Harmony Biosciences Holdings, Inc.

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
39.05 ^USD	+1.32%		+7.13%	+13.48%

Jan. 15	Harmony Biosciences Holdings, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 11:15 AM
Jan. 13	Harmony Biosciences Reports Preliminary Q4, 2024 Net Product Revenue; 2025 Revenue Guidance Issued	MT

Harmony Biosciences Holdings, Inc. Re-Iterates Revenue Guidance for the Full Year 2024

October 29, 2024 at 07:50 am EDT

Harmony Biosciences Holdings, Inc. re-iterated revenue guidance for the full year 2024. For the year, The company expects full year 2024 net product revenue of $700 million to $720 million.

Latest news about Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 11:15 AM	Jan. 15
Harmony Biosciences Reports Preliminary Q4, 2024 Net Product Revenue; 2025 Revenue Guidance Issued	Jan. 13	MT
Harmony Biosciences Holdings, Inc. Announces Preliminary, Unaudited Net Product Revenues for the Fourth Quarter and Full Year Ended December 31, 2024	Jan. 13	CI
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2025	Jan. 13	CI
HC Wainwright Initiates Harmony Biosciences at Buy With $75 Price Target	Dec. 17	MT
Harmony Biosciences Holdings Launches Secondary Common Stock Offering	24-10-30	MT
Harmony Biosciences Holdings, Inc., Q3 2024 Earnings Call, Oct 29, 2024	24-10-29
Harmony Biosciences Holdings Q3 Adjusted Earnings, Net Product Revenue Increase	24-10-29	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	24-10-29	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-29	CI
Harmony Biosciences Holdings, Inc. Re-Iterates Revenue Guidance for the Full Year 2024	24-10-29	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Reports Q3 EPS $1.03	24-10-29	MT
Harmony Biosciences Holdings, Inc. - Analyst/Investor Day	24-10-01
Harmony Biosciences Boosted by Narcolepsy Treatment, Diversification Outlook. UBS Says	24-09-10	MT
UBS Initiates Harmony Biosciences Holdings at Buy With $56 Price Target	24-09-10	MT
Mizuho Securities Adjusts Harmony Biosciences Price Target to $42 From $40, Maintains Outperform Rating	24-08-07	MT
Harmony Biosciences' Q2 Adjusted EPS, Revenue Rise; Shares Gain	24-08-06	MT
Harmony Biosciences Holdings, Inc., Q2 2024 Earnings Call, Aug 06, 2024	24-08-06
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	24-08-06	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-06	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q2 EPS $0.20, vs. Street Est of $0.12	24-08-06	MT
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	24-08-06	CI
Harmony Biosciences Holdings, Inc. Announces Resignation of Jack Bech Nielsen from Board	24-07-01	CI
Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration Action Deny the Citized Petition for WAKIX®?	24-06-25	CI
Harmony Biosciences Says FDA Approves Supplemental NDA for Pediatric Narcolepsy Treatment	24-06-24	MT

Chart Harmony Biosciences Holdings, Inc.

Duration

Period

Chart Harmony Biosciences Holdings, Inc.

HRMY: Dynamic Chart

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Employees

246

Sector

Pharmaceuticals

Calendar

2025-02-18 - Q4 2024 Earnings Release (Projected)

More about the company